HRP20160387T1 - Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor - Google Patents
Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor Download PDFInfo
- Publication number
- HRP20160387T1 HRP20160387T1 HRP20160387TT HRP20160387T HRP20160387T1 HR P20160387 T1 HRP20160387 T1 HR P20160387T1 HR P20160387T T HRP20160387T T HR P20160387TT HR P20160387 T HRP20160387 T HR P20160387T HR P20160387 T1 HRP20160387 T1 HR P20160387T1
- Authority
- HR
- Croatia
- Prior art keywords
- degrees
- alk
- salt
- compound
- positive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607305P | 2012-03-06 | 2012-03-06 | |
| PCT/US2013/029304 WO2013134353A1 (en) | 2012-03-06 | 2013-03-06 | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
| EP13710258.8A EP2822939B1 (en) | 2012-03-06 | 2013-03-06 | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160387T1 true HRP20160387T1 (hr) | 2016-05-20 |
Family
ID=47892060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160387TT HRP20160387T1 (hr) | 2012-03-06 | 2013-03-06 | Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US9132128B2 (enExample) |
| EP (2) | EP3056494B1 (enExample) |
| JP (2) | JP6016953B2 (enExample) |
| KR (1) | KR102068374B1 (enExample) |
| CN (2) | CN104159894B (enExample) |
| AU (1) | AU2013229995B2 (enExample) |
| CA (1) | CA2865420C (enExample) |
| CL (1) | CL2014002353A1 (enExample) |
| CY (1) | CY1117565T1 (enExample) |
| DK (1) | DK2822939T3 (enExample) |
| EA (2) | EA025859B1 (enExample) |
| ES (2) | ES2681487T3 (enExample) |
| HR (1) | HRP20160387T1 (enExample) |
| HU (1) | HUE027976T2 (enExample) |
| IL (2) | IL234239A (enExample) |
| ME (1) | ME02460B (enExample) |
| MX (2) | MX372740B (enExample) |
| MY (1) | MY177290A (enExample) |
| NZ (1) | NZ630251A (enExample) |
| PH (1) | PH12014501979A1 (enExample) |
| PL (1) | PL2822939T3 (enExample) |
| RS (1) | RS54689B1 (enExample) |
| SG (2) | SG10201507865QA (enExample) |
| SI (1) | SI2822939T1 (enExample) |
| SM (1) | SMT201600134B (enExample) |
| UA (1) | UA115052C2 (enExample) |
| WO (1) | WO2013134353A1 (enExample) |
| ZA (1) | ZA201406147B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2865420C (en) * | 2012-03-06 | 2020-06-02 | Cephalon, Inc. | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
| JP6783224B2 (ja) | 2014-04-04 | 2020-11-11 | デル マー ファーマシューティカルズ | 肺の非小細胞癌腫及び卵巣癌を処置するためのジアンヒドロガラクチトール及びその類縁体又は誘導体の使用 |
| WO2016105529A1 (en) | 2014-12-23 | 2016-06-30 | Cephalon, Inc. | Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives |
| US12257245B2 (en) | 2018-08-07 | 2025-03-25 | In3Bio Ltd. | Methods and compositions for inhibition of EGF/EGFR pathway in combination with anaplastic lymphoma kinase inhibitors |
| WO2024178339A2 (en) * | 2023-02-23 | 2024-08-29 | The Regents Of The University Of Michigan | Methods for treating neuroblastoma with a dual anaplastic lymphoma kinase and focal adhesion kinase inhibitor |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004259012C1 (en) | 2003-07-23 | 2012-08-02 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| TWI378923B (en) | 2003-08-15 | 2012-12-11 | Novartis Ag | Pyrimidine derivatives |
| CA2553785C (en) * | 2004-02-14 | 2011-02-08 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| US7973061B2 (en) | 2004-03-31 | 2011-07-05 | Exelixis, Inc. | Anaplastic lymphoma kinase modulators and methods of use |
| JP2009528295A (ja) * | 2006-02-24 | 2009-08-06 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｊａｋ経路の阻害のための組成物および方法 |
| ES2555803T3 (es) | 2006-10-23 | 2016-01-08 | Cephalon, Inc. | Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met |
| BRPI0722383A2 (pt) * | 2006-12-08 | 2012-06-05 | Irm Llc | compostos inibidores de proteìna quinase, composições contendo os mesmos bem como seus usos |
| AP2009005010A0 (en) * | 2007-04-18 | 2009-10-31 | Pfizer Prod Inc | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
| ES2668775T3 (es) * | 2009-06-10 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Compuestos tetracíclicos |
| CA2865420C (en) * | 2012-03-06 | 2020-06-02 | Cephalon, Inc. | Fused bicyclic 2,4-diaminopyrimidine derivative as a dual alk and fak inhibitor |
| KR101446742B1 (ko) * | 2012-08-10 | 2014-10-01 | 한국화학연구원 | Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
| WO2016105529A1 (en) * | 2014-12-23 | 2016-06-30 | Cephalon, Inc. | Methods for preparing fused bicyclic 2, 4-diaminopyrimidine derivatives |
-
2013
- 2013-03-06 CA CA2865420A patent/CA2865420C/en active Active
- 2013-03-06 ES ES15202516.9T patent/ES2681487T3/es active Active
- 2013-03-06 EA EA201491641A patent/EA025859B1/ru not_active IP Right Cessation
- 2013-03-06 DK DK13710258.8T patent/DK2822939T3/en active
- 2013-03-06 NZ NZ630251A patent/NZ630251A/en unknown
- 2013-03-06 ME MEP-2016-68A patent/ME02460B/me unknown
- 2013-03-06 SI SI201330151T patent/SI2822939T1/sl unknown
- 2013-03-06 ES ES13710258T patent/ES2570976T3/es active Active
- 2013-03-06 MY MYPI2014002428A patent/MY177290A/en unknown
- 2013-03-06 AU AU2013229995A patent/AU2013229995B2/en active Active
- 2013-03-06 PL PL13710258T patent/PL2822939T3/pl unknown
- 2013-03-06 UA UAA201410832A patent/UA115052C2/uk unknown
- 2013-03-06 KR KR1020147027590A patent/KR102068374B1/ko active Active
- 2013-03-06 CN CN201380012764.6A patent/CN104159894B/zh active Active
- 2013-03-06 WO PCT/US2013/029304 patent/WO2013134353A1/en not_active Ceased
- 2013-03-06 HU HUE13710258A patent/HUE027976T2/en unknown
- 2013-03-06 MX MX2017006206A patent/MX372740B/es unknown
- 2013-03-06 MX MX2014010613A patent/MX347772B/es active IP Right Grant
- 2013-03-06 CN CN201610591742.5A patent/CN106166155B/zh active Active
- 2013-03-06 SG SG10201507865QA patent/SG10201507865QA/en unknown
- 2013-03-06 EP EP15202516.9A patent/EP3056494B1/en active Active
- 2013-03-06 JP JP2014561069A patent/JP6016953B2/ja not_active Expired - Fee Related
- 2013-03-06 SG SG11201405371PA patent/SG11201405371PA/en unknown
- 2013-03-06 EA EA201691574A patent/EA033124B1/ru not_active IP Right Cessation
- 2013-03-06 EP EP13710258.8A patent/EP2822939B1/en active Active
- 2013-03-06 HR HRP20160387TT patent/HRP20160387T1/hr unknown
- 2013-03-06 RS RS20160238A patent/RS54689B1/sr unknown
-
2014
- 2014-08-21 ZA ZA2014/06147A patent/ZA201406147B/en unknown
- 2014-08-21 IL IL234239A patent/IL234239A/en active IP Right Grant
- 2014-09-02 US US14/474,928 patent/US9132128B2/en active Active
- 2014-09-05 PH PH12014501979A patent/PH12014501979A1/en unknown
- 2014-09-05 CL CL2014002353A patent/CL2014002353A1/es unknown
-
2015
- 2015-08-12 US US14/824,750 patent/US9339502B2/en active Active
-
2016
- 2016-05-04 US US15/146,164 patent/US9623026B2/en not_active Expired - Fee Related
- 2016-05-10 SM SM201600134T patent/SMT201600134B/it unknown
- 2016-05-10 CY CY20161100390T patent/CY1117565T1/el unknown
- 2016-09-27 JP JP2016188585A patent/JP2017039741A/ja active Pending
-
2017
- 2017-03-07 US US15/451,960 patent/US10111872B2/en active Active
- 2017-05-18 IL IL252364A patent/IL252364B/en active IP Right Grant
-
2018
- 2018-10-26 US US16/172,368 patent/US10632119B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02460B (me) | Spojeni biciklični 2,4-diaminopirimidin derivat kao dualni alk i fak inhibitor | |
| HRP20241590T1 (hr) | Supstituirani heterociklički fuzirani ciklički spoj, postupak njegove pripreme i njegova farmaceutska uporaba | |
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| HRP20190831T1 (hr) | Mješavina rp/sp gemcitabin-[fenil-(benziloksi-l-alaninil)]-fosfata | |
| BR112015023705A2 (pt) | composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) | |
| PH12019500830A1 (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| JP2015509540A5 (enExample) | ||
| HRP20180455T1 (hr) | Natrijev (2r, 5s, 13ar) -7, 9-diokso-10- ( (2,4,6-trifluorobenzil) karbamoil) -2, 3, 4, 5, 7, 9, 13, 13a-oktahidro-2, 5-metanopirido [1’,2’ : 4.5]pirazino [2,1-b]oksazepin-8-olat | |
| PH12015501517A1 (en) | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| HRP20210681T1 (hr) | Kristalne soli (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroizokinolin-2(1h)-il)-2-hidroksipropil)pirimidin-4-karboksamida | |
| EA201591301A1 (ru) | Новые пиримидиновые и пиридиновые соединения и их применение | |
| NZ604480A (en) | Morpholino pyrimidines and their use in therapy | |
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| ME02757B (me) | Indoli | |
| MX2015011818A (es) | Inhibidores quinazolinicos de formas mutadas activantes del receptor del factor de crecimiento epidermico. | |
| PH12013500265A1 (en) | Pharmaceutically active compounds as axl inhibitors | |
| MX2014014106A (es) | Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral. | |
| UA111604C2 (uk) | ЗАМІЩЕНІ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНОВІ СОЛІ | |
| MX2013008431A (es) | Antagonista del receptor de mineralocorticoides. | |
| WO2013004995A8 (en) | Pyrimidinone compounds and their use | |
| HRP20161522T1 (hr) | Derivati 6.7-dialkoksi kinazolina korisni za liječenje poremećaja povezanih s rakom | |
| MX2016002795A (es) | Compuestos de triazolona y usos de los mismos. | |
| MX2016001896A (es) | Derivados de amida como agonistas del receptor del ácido lisofosfatídico. | |
| MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. |